Rapid point-of-care testing for SARS-CoV-2 in a community screening setting shows low sensitivity.
Adult
Aged
Betacoronavirus
/ isolation & purification
COVID-19
COVID-19 Testing
Clinical Laboratory Techniques
/ standards
Community Health Services
Coronavirus Infections
/ diagnosis
Disease Outbreaks
Female
Humans
Male
Mass Screening
/ methods
Middle Aged
Pandemics
Pneumonia, Viral
/ diagnosis
Point-of-Care Testing
Polymerase Chain Reaction
SARS-CoV-2
Sensitivity and Specificity
Time Factors
COVID-19
Coronavirus
Outbreak
Rapid test
SARS-CoV-2
Journal
Public health
ISSN: 1476-5616
Titre abrégé: Public Health
Pays: Netherlands
ID NLM: 0376507
Informations de publication
Date de publication:
May 2020
May 2020
Historique:
received:
03
04
2020
accepted:
06
04
2020
pubmed:
26
4
2020
medline:
2
6
2020
entrez:
26
4
2020
Statut:
ppublish
Résumé
With the current SARS-CoV2 outbreak, countless tests need to be performed on potential symptomatic individuals, contacts and travellers. The gold standard is a quantitative polymerase chain reaction (qPCR)-based system taking several hours to confirm positivity. For effective public health containment measures, this time span is too long. We therefore evaluated a rapid test in a high-prevalence community setting. Thirty-nine randomly selected individuals at a COVID-19 screening centre were simultaneously tested via qPCR and a rapid test. Ten previously diagnosed individuals with known SARS-CoV-2 infection were also analysed. The evaluated rapid test is an IgG/IgM-based test for SARS-CoV-2 with a time to result of 20 min. Two drops of blood are needed for the test performance. Of 49 individuals, 22 tested positive by repeated qPCR. In contrast, the rapid test detected only eight of those positive correctly (sensitivity: 36.4%). Of the 27 qPCR-negative individuals, 24 were detected correctly (specificity: 88.9%). Given the low sensitivity, we recommend not to rely on an antibody-based rapid test for public health measures such as community screenings.
Identifiants
pubmed: 32334183
pii: S0033-3506(20)30114-1
doi: 10.1016/j.puhe.2020.04.009
pmc: PMC7165286
pii:
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
170-172Commentaires et corrections
Type : CommentIn
Informations de copyright
Copyright © 2020 The Royal Society for Public Health. Published by Elsevier Ltd. All rights reserved.
Références
Eur J Nucl Med Mol Imaging. 2020 May;47(5):1275-1280
pubmed: 32107577
Lancet Infect Dis. 2020 Apr 27;:
pubmed: 32353347
Zhonghua Xin Xue Guan Bing Za Zhi. 2020 Mar 02;48(0):E004
pubmed: 32120458
J Clin Microbiol. 2020 Apr 23;58(5):
pubmed: 32132196
Clin Infect Dis. 2020 Mar 28;:
pubmed: 32221519
Lancet. 2020 Mar 7;395(10226):762-764
pubmed: 32105610
N Engl J Med. 2020 Mar 26;382(13):1278-1280
pubmed: 32069388
N Engl J Med. 2020 Apr 30;382(18):1708-1720
pubmed: 32109013
J Hosp Infect. 2020 Mar 5;:
pubmed: 32147407